The sugar reducing agent Yanuvia shows its effectiveness when ingested. The active ingredient has differences in the chemical structure and pharmacological properties of similar insulin preparations, sulfonylureas, amylin, γ-receptor agonists and many others. Etc. By suppressing dipeptidyl peptidase, the active component increases the level of incretin hormones that are produced inside the intestine. Usually the amount of such hormones increases as a result of eating. Incretinovye substances are considered an element of the internal physiological process of glucose homeostasis.
If the blood sugar level is exceeded or is within normal limits, incretin hormones stimulate active production of insulin. In addition, its release by β-cells in the pancreas is activated, which is explained by the action of control intracellular processes.
Also, the drug Yanuvia helps to inhibit the excessive release of glucagon. Lowering the glucagon level while increasing the amount of insulin leads to a decrease in the production of glucose in the liver. As a result of such processes, glycemia decreases.
At a low glucose level, the above properties do not appear.
The active component of Yanuvia prevents the processes of hydrolysis of incretin hormones with the enzyme dipeptidyl peptidase. As a consequence, plasma concentrations of GLP 1 and HIC increase, glucose-dependent insulin production increases and glucagon release is reduced.